Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emicizumab

Roche - Basel

Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

First-in-class antibody drug conjugate

Roche Basel Switzerland

Roche/GE’s digital medicine alliance bears first fruit

While new player enters liquid biopsy market

Biomarin

BioMarin eyes haemophilia therapy filing, but data scares investors

Doubts remain on longer term efficacy

- PMLiVE

Am I wrong to be apprehensive about gene therapy?

Is the introduction of gene therapy going to be smooth sailing? Origin's Strategic Solutions Director, Su Smith, shares her thoughts.

Bedrock Healthcare Communications

- PMLiVE

Genentech forges $800m autoimmune alliance with Parvus

Big vote of confidence in novel platform

- PMLiVE

Roche and NHS England hail pricing deal on MS drug Ocrevus

Another pricing deal on high cost medicine

- PMLiVE

Sobi shows strong growth despite haemophilia competition

Looking to M&A for continued growth

Roche Basel Switzerland

Hemlibra off to a flyer as Roche raises 2019 forecasts

Drug has made almost as much in this quarter as it did in 2018

Roche Basel Switzerland

Roche says ‘discovery proteomics’ is heading for clinical trials

Tech has potential to identify novel biomarkers

- PMLiVE

Sanofi exits R&D pact with Alnylam on rare disease

Exit also frees up $700m equity investment

- PMLiVE

Tecentriq combo shows promise in triple negative breast cancer

Tumours reduced in 73% of trial participants

- PMLiVE

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Safety concerns could hit blockbuster expectations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links